25 April 2018 - This report presents a summary of responses to the Therapeutic Products Directorate's consultation on proposals for prescription drug transparency. 

The consultation was held online between September 28 and October 28, 2017.

The purpose of the consultation was to seek input on five proposals related to drug product transparency initiatives. The consultation was open to the public, health organizations, industry, and other interested stakeholders.

The input received will inform the work that Health Canada is doing to update and expand its current transparency initiatives. The first two proposals are designed to improve transparency of generic drug submissions (abbreviated new drug submissions). The other three proposals relate to changes to existing transparency initiatives for drug submissions.

Read TPD Announcement